Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies

Alan Ashworth(University of California, San Francisco), Marc van der Vijver(Amsterdam UMC Location University of Amsterdam), Rachel Brough(Institute of Cancer Research), Jessica Frankum(Institute of Cancer Research), Hugo M. Horlings, Ilirjana Bajrami(Institute of Cancer Research), Rachael Natrajan(Institute of Cancer Research), Nicholas C. Turner(Institute of Cancer Research), David Sims(Institute of Cancer Research), Caterina Marchiò(Candiolo Cancer Institute), Alan Mackay(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Rachel Sharpe(Guy's Hospital), Daniel Wetterskog(CRUK Lung Cancer Centre of Excellence), Christopher J. Lord(Institute of Cancer Research), Fabien Reyal(Université Paris Sciences et Lettres), Maryou Lambros(Institute of Cancer Research)
Oncogene
January 21, 2013
10.1038/onc.2012.625
Cited by 24

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k